View:
Download DOC
Download PDF
Download XLS

 

 

Securities and Exchange Commission

Washington, DC 20549

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

 

CytomX Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

 

 

 

23284F105

(CUSIP Number)

 

 

 

July 15, 2022

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

 

xRule 13d-1(c)

 

¨Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

Page 1 of 8
 

 

CUSIP No. 23284F105

 

 

 13G Page 2 of 8 Pages

1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

TANG CAPITAL PARTNERS, LP

 

2 Check the Appropriate Box if a Member of a Group*

(a) ¨

 

(b) x

 

3 SEC Use Only
4

Citizenship or Place of Organization

 

DELAWARE

 

 

Number of

 5

Sole Voting Power

 

0 

Shares

BENEFICIALLY
Owned by

 6

Shared Voting Power

 

3,470,900

Each Reporting
Person with		 7

Sole Dispositive Power

 

0 

  8

Shared Dispositive Power

 

3,470,900 

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

3,470,900 

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

5.3% 

12

type of reporting person

 

pN 

 

Page 2 of 8
 

 

CUSIP No. 23284F105

 

 

 13G Page 3 of 8 Pages

1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

Tang Capital Management, LLC

 

2 Check the Appropriate Box if a Member of a Group*

(a) ¨

 

(b) x

 

3 SEC Use Only
4

Citizenship or Place of Organization

 

DELAWARE

 

 

Number of

 5

Sole Voting Power

 

0 

Shares

BENEFICIALLY
Owned by

 6

Shared Voting Power

 

3,470,900

Each Reporting

Person with

 7

Sole Dispositive Power

 

0 

  8

Shared Dispositive Power

 

3,470,900 

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

3,470,900 

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

5.3% 

12

type of reporting person

 

OO 

 

Page 3 of 8
 

 

CUSIP No. 23284F105

 

 

 13G Page 4 of 8 Pages

1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

Kevin Tang

 

2 Check the Appropriate Box if a Member of a Group*

(a) ¨

 

(b) x

 

3 SEC Use Only
4

Citizenship or Place of Organization

 

united states

 

 

Number of

 5

Sole Voting Power

 

0 

Shares

BENEFICIALLY
Owned by

 6

Shared Voting Power

 

3,470,900

Each Reporting
Person with		 7

Sole Dispositive Power

 

0 

  8

Shared Dispositive Power

 

3,470,900 

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

3,470,900 

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

5.3% 

12

type of reporting person

 

IN 

 

Page 4 of 8
 

 

Item 1(a).Name of Issuer:

 

CytomX Therapeutics, Inc., a Delaware corporation (the “Issuer”)

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080

 

Item 2(a).Name of Person Filing:

 

This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

 

Item 2(b).Address of Principal Business Office or, if none, Residence:

 

4747 Executive Drive, Suite 210, San Diego, CA 92121

 

Item 2(c).Citizenship:

 

Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

 

Item 2(d).Title of Class of Securities:

 

Common Stock, par value $0.00001 per share (the “Common Stock”)

 

Item 2(e).CUSIP Number: 23284F105

 

Item 3.Not applicable.

 

Item 4.Ownership.

 

(a)Amount Beneficially Owned:

 

Tang Capital Partners. Tang Capital Partners beneficially owns 3,470,900 shares of the Issuer’s Common Stock.

 

Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

 

Tang Capital Management. Tang Capital Management beneficially owns 3,470,900 shares of the Issuer’s Common Stock.

 

Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

 

Kevin Tang. Kevin Tang beneficially owns 3,470,900 shares of the Issuer’s Common Stock.

 

Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

 

Page 5 of 8
 

 

The percentages used herein are based on 65,398,355 shares of Common Stock outstanding as of April 29, 2022, as set forth in the Issuer’s Quarterly Report on Form 10-Q that was filed with the Securities and Exchange Commission on May 5, 2022.

 

(b)Percent of Class:

 

Tang Capital Partners 5.3%
Tang Capital Management 5.3%
Kevin Tang 5.3%

 

(c)Number of shares as to which such person has:

 

(i)       sole power to vote or to direct the vote:

 

  Tang Capital Partners 0 shares
  Tang Capital Management 0 shares
  Kevin Tang 0 shares

 

(ii)       shared power to vote or to direct the vote:

 

  Tang Capital Partners 3,470,900 shares
  Tang Capital Management 3,470,900 shares
  Kevin Tang 3,470,900 shares

 

(iii)     sole power to dispose or to direct the disposition of:

 

  Tang Capital Partners 0 shares
  Tang Capital Management 0 shares
  Kevin Tang 0 shares

 

(iv)     shared power to dispose or to direct the disposition of:

 

  Tang Capital Partners 3,470,900 shares
  Tang Capital Management 3,470,900 shares
  Kevin Tang 3,470,900 shares

 

Item 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.Notice of Dissolution of Group.

 

Not applicable.

 

Page 6 of 8
 

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

Page 7 of 8
 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Date: July 25, 2022  

 

 

TANG CAPITAL PARTNERS, LP

 

By:  Tang Capital Management, LLC, its General Partner  
     
     
By: /s/ Kevin Tang  
  Kevin Tang, Manager  
     
     
TANG CAPITAL MANAGEMENT, LLC  
     
     
By: /s/ Kevin Tang  
  Kevin Tang, Manager  
     
     
/s/ Kevin Tang  
Kevin Tang  

 

 

Page 8 of 8

 

 

 

 

 

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

     In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of CytomX Therapeutics, Inc. and further agree to the filing of this Joint Filing Agreement as an exhibit thereto. In addition, each party to this Joint Filing Agreement expressly authorizes each other party to this Joint Filing Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

 

Date: July 25, 2022 TANG CAPITAL PARTNERS, LP
 		  
  By:   Tang Capital Management, LLC    
  Its:   General Partner   
     
  By:   /s/ Kevin Tang  
    Name:   Kevin Tang   
    Title:   Manager   
 
  TANG CAPITAL MANAGEMENT, LLC
 		  
  By:   /s/ Kevin Tang  
    Name:   Kevin Tang   
    Title:   Manager   
     
  /s/ Kevin Tang  
  Name:   Kevin Tang